Interventional Oncology Market on Track for Strong Growth, Estimated to Grow at 8.8% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Interventional Oncology Market Through 2025?
In recent times, there has been a robust growth in the size of the interventional oncology market. The market, which is projected to develop from $2.49 billion in 2024 to $2.72 billion in 2025, will observe a compound annual growth rate (CAGR) of 9.2%. This growth in the past period is credited to factors like the escalating worldwide prevalence of cancer, growing acceptance of minimally invasive procedures, an increment in healthcare spending in developing economies, a surge in the need for image-guided therapeutics, and a heightened awareness of the benefits of interventional oncology.

What's the Projected Size of the Global Interventional Oncology Market by 2029?
The growth of the interventional oncology market is predicted to be robust in the upcoming years, reaching $3.82 billion by 2029 at a compound annual growth rate of 8.8%. This surge in the forecast period is attributed to the escalated demand for outpatient oncology processes, an upward trend in using immuno-oncology in combination therapies, a rise in clinical trials for image-guided therapies, and increased access to interventional oncology in developing markets, along with the expanding role of precision medicine in drafting treatment plans. Key trends forecasted during this period include advancements in image-guided ablation technologies, the creation of diagnostic tools empowered by artificial intelligence, the inception of innovative targeted drug-delivery systems, progression in minimally invasive treatment apparatus, and the rapid development of personalized oncology treatment schemes.

View the full report here:
https://www.thebusinessresearchcompany.com/report/interventional-oncology-global-market-report

Top Growth Drivers in the Interventional Oncology Industry: What's Accelerating the Market?
The escalating incidence of cancer is predicted to boost the expansion of the interventional oncology market. Incidence of cancer applies to the total count of individuals who are alive having been recently or previously diagnosed with cancer at a certain period. Such a rate is augmenting because of lifestyle-linked risks such as unhealthy diets, smoking, alcohol intake, and contact with environmental pollutants, raising the likelihood of different cancers' onset. Interventional oncology aids in cancer therapy by offering minimally invasive, targeted treatments that concentrate directly on tumors. It enhances patients' outcomes by decreasing harm to healthy tissue and allows quicker recovery periods compared to conventional treatments. For instance, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in July 2024 that Australia saw a rise in cancer diagnoses to 160,570 in 2022, up by 3,789 cases from 156,781 in 2021. Hence, the rising incidence of cancer propels the growth of the interventional oncology market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27318&type=smp

What Trends Will Shape the Interventional Oncology Market Through 2029 and Beyond?
Key players in the interventional oncology market are concentrating on the innovation of sophisticated products such as microcatheter-based embolization systems. These devices are designed to provide accurate cancer treatment while causing minimal harm to the nearby healthy tissue. In medical terms, microcatheter-based embolization systems use small, flexible tubes to pinpoint the delivery of embolic substances directly into blood vessels to lessen or obstruct blood flow, commonly for the treatment of tumors, vascular irregularities, or hemorrhages. To illustrate, Terumo Corporation, a medical device firm headquartered in Japan, unveiled the Occlusafe balloon occlusion catheter in March 2025. This was built on their cutting-edge Balloon-TACE (B-TACE) therapy primarily used to treat liver cancer, and specifically hepatocellular carcinoma (HCC). The unique microcatheter uses the pressure gradient impact to divert blood flow towards the microcirculation, allowing higher amounts of therapeutic substances to reach the tumor while avoiding unnecessary embolization. This focused approach aims to enhance clinical results in challenging-to-handle liver cancer incidences by enhancing the accuracy of drug delivery and providing superior imaging during treatments.

What Are the Main Segments in the Interventional Oncology Market?
The interventional oncology market covered in this report is segmented

1) By Type: Radiation Therapy Devices, Ablation Devices, Embolization Devices
2) By Technology Type: Ultrasound, Computed Tomography Guided, Magnetic Resonance-Guided
3) By Procedure: Tumor Ablation, Tumor Biopsy, Vascular Interventions, Palliative Care
4) By Application Areas: Liver Cancer, Lung Cancer, Kidney Cancer, Pancreatic Cancer, Prostate Cancer
5) By End-Users: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Research And Academic Institutions

Subsegments:
1) By Radiation Therapy Devices: Linear Accelerators, Proton Therapy Systems, Brachytherapy Devices
2) By Ablation Devices: Radiofrequency Ablation Devices, Microwave Ablation Devices, Cryoablation Devices, Irreversible Electroporation Systems
3) By Embolization Devices: Microspheres, Coil Embolization Devices, Liquid Embolic Agents, Embolic Protection Devices

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27318&type=smp

Which Top Companies are Driving Growth in the Interventional Oncology Market?
Major companies operating in the interventional oncology market are Johnson & Johnson, Siemens Healthineers AG, Stryker Corporation, GE HealthCare Technologies Inc., Boston Scientific Corporation, Terumo Corporation, Hologic Inc., Teleflex Incorporated, Lantheus Holdings Inc., Penumbra Inc., Merit Medical Systems Inc., Guerbet S.A, Asahi Intecc Co. Ltd., AngioDynamics Inc., Sirtex Medical Limited., Delcath Systems Inc., ABK Biomedical Inc., Profound Medical Inc., IceCure Medical Ltd., Minimax Medical Holding Group.

Which Regions Will Dominate the Interventional Oncology Market Through 2029?
North America was the largest region in the interventional oncology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interventional oncology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27318

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.